看板 nCoV2019 關於我們 聯絡資訊
完整標題:Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine 發稿單位:USA CDC &FDA 發稿時間:Tuesday, April 13, 2021 原文連結:https://www.cdc.gov/media/releases/2021/s0413-JJ-vaccine.html The following statement is attributed to Dr. Anne Schuchat, Principal Deputy Director of the CDC and Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research As of April 12, more than 6.8 million doses of the Johnson & Johnson (Janssen ) vaccine have been administered in the U.S. CDC and FDA are reviewing data involving six reported U.S. cases of a rare and severe type of blood clot in individuals after receiving the J&J vaccine. In these cases, a type of blood clot called cerebral venous sinus thrombosis (CVST) was seen in combination with low levels of blood platelets (thrombocytopenia). All six cases occurred among women between the ages of 18 and 48, and symptoms occurred 6 to 13 days after vaccination. Treatment of this specific type of blood clot is different from the treatment that might typically be administered. Usually, an anticoagulant drug called heparin is used to treat blood clots. In this setting, administration of heparin may be dangerous, and alternative treatments need to be given. CDC will convene a meeting of the Advisory Committee on Immunization Practices (ACIP) on Wednesday to further review these cases and assess their potential significance. FDA will review that analysis as it also investigates these cases. Until that process is complete, we are recommending a pause in the use of this vaccine out of an abundance of caution. This is important, in part, to ensure that the health care provider community is aware of the potential for these adverse events and can plan for proper recognition and management due to the unique treatment required with this type of blood clot. Right now, these adverse events appear to be extremely rare. COVID-19 vaccine safety is a top priority for the federal government, and we take all reports of health problems following COVID-19 vaccination very seriously. People who have received the J&J vaccine who develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider. Health care providers are asked to report adverse events to the Vaccine Adverse Event Reporting System at https://vaers.hhs.gov/reportevent.htmlexternal icon. CDC and FDA will provide additional information and answer questions later today at a media briefing. A recording of that media call will be available on the FDA’s YouTube channel. 簡單整理: 在接種疫苗後三週內出現嚴重的頭痛,腹痛,大腿痛,胸悶或呼吸急促,應儘速就醫, 鑒於採用類似技術的AZ也有類似關聯性出現, 有打AZ疫苗的出現類似情形最好也趕快就醫~~ 另外,常見的肝素治療血栓在該情形不建議 -- ※ 發信站: 批踢踢實業坊(ptt.cc), 來自: 64.106.111.101 (美國) ※ 文章網址: https://www.ptt.cc/bbs/nCoV2019/M.1618463927.A.151.html ※ 編輯: dreamgirl (64.106.111.101 美國), 04/15/2021 13:21:17
sdiaa: 我還以為英國金毛首相又怎麼了~ 211.75.158.91 04/15 16:35